Can a dialysis Add-On help sepsis patients by draining dangerous iron?

NCT ID NCT07236463

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether adding an iron-binding drug (MEX-CD1) to dialysis fluid can safely remove extra iron from the blood of adults in the ICU with sepsis and acute kidney injury. Each participant will receive two 24-hour dialysis sessions—one with standard fluid and one with the drug—to compare iron removal and safety. The goal is to see if this approach can reduce harmful iron levels that may worsen inflammation and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY SEPSIS

Contacts and locations

Locations

CHU de Nîmes
RECRUITING

Nîmes, 30029, France
Nimes University Hospital
NOT_YET_RECRUITING

Nîmes, Gard, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.